Information  X 
Enter a valid email address

Renalytix PLC (RENX)


Wednesday 08 December, 2021

Renalytix PLC

Director/PDMR Shareholding

RNS Number : 9024U
Renalytix PLC
08 December 2021

Renalytix plc

("Renalytix" or the "Company")  


Director/PDMR Dealing


New York, 8 December 2021 - Renalytix (LSE: RENX) announces that it has been advised of the purchase by James McCullough, the Company's Chief Executive Officer, of 950 American Depositary Shares ("ADS") in open market purchases using personal funds, each representing two ordinary shares of £0.0025 each in the capital of the Company ("Ordinary Shares"), at an aggregate price of $15.04 per ADS.


Following completion of the purchase, James McCullough is interested in 2,742,010 Ordinary Shares representing 3.8% of the current issued share capital of the Company.


For further information, please contact:  


Renalytix plc

James McCullough, CEO   

Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)  

Tel: 020 7710 7600

Alex Price / Nicholas Moore   

Investec Bank plc (Joint Broker)  

Tel: 020 7597 4000

Gary Clarence / Daniel Adams  

Walbrook PR Limited  

Tel: 020 7933 8780  or  [email protected]

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / 07584 391 303


About KidneyIntelX

KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.


About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit ). For more information, visit .







The information contained in this notification is disclosed in accordance with the requirements of MAR.



Details of the person discharging managerial responsibilities/person closely associated




James McCullough


Reason for the notification




Chief Executive Officer




Initial notification /Amendment


Initial Notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




Renalytix plc



Legal Entity Identifier




Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument


Identification code

ADS', each ADS representing two Ordinary Shares of £0.0025 each.






Nature of the transaction

Purchase of ADS'





US Dollar


Price(s) and volume(s)







100 ADS (representing 200 Ordinary Shares)




100 ADS (representing 200 Ordinary Shares)


250 ADS (representing 500 Ordinary Shares)


500 ADS (representing 1000 Ordinary Shares)


Aggregated information

- Aggregated volume

- Price

- Aggregated total



950 ADS (representing 1900 Ordinary Shares)




Date of the transaction

8 December 2021



Place of the transaction

Nasdaq Stock Exchange





This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t